Tactile Systems Technology Inc (TCMD)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Tactile Systems Technology Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 28.20 $ — 79% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 10.1% failed
- More than 10% revenue growth is expected for the coming year 9.0% failed
- Share count grows by less than 3% a year 5.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 24.7% failed
- Gross margin at 40% or higher and without meaningful erosion 75.2% passed
- Goodwill from acquisitions does not grow faster than revenue 11.3% passed
- Net debt below twice EBITDA 67 m net cash passed
- Operating cash flow covers the profits of the last three years 55 m passed
- Return on capital at 15% or higher, or up versus two years ago 12.6% passed
- Insiders hold at least 10% or are net buyers 2.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 40.1% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.10 | 1.05 – 1.14 | 365 | 31.6% | 2 |
| 12/31/2027 | 1.51 | 1.35 – 1.66 | 398 | 37.4% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.40 | 13.40 | 86 | 10.20 | 11.40 | 16 | 16 |
| 2025: Q1 | -0.13 | – | 61 | 0.30 | -4.90 | 0 | 0 |
| 2025: Q2 | 0.14 | -22.40 | 79 | 7.80 | 4.10 | 15 | 14 |
| 2025: Q3 | 0.36 | 71.60 | 86 | 17.30 | 9.60 | 10 | 9 |
| 2025: Q4 | 0.46 | 16.20 | 104 | 21.00 | 10.30 | 17 | 17 |
| 2026: Q1 | -0.08 | – | 75 | 22.80 | -2.30 | 0 | -1 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 85 | 4 | 3 | 0.17 | 7 | 60 | 74 |
| 2017 | 109 | 4 | 6 | 0.31 | 4 | 73 | 88 |
| 2018 | 144 | 3 | 7 | 0.34 | 9 | 89 | 107 |
| 2019 | 189 | 11 | 11 | 0.56 | 3 | 113 | 152 |
| 2020 | 187 | -4 | -1 | -0.03 | 3 | 125 | 174 |
| 2021 | 208 | -2 | -12 | -0.60 | 3 | 128 | 244 |
| 2022 | 247 | -13 | -18 | -0.89 | 5 | 121 | 255 |
| 2023 | 274 | 18 | 29 | 1.23 | 36 | 194 | 281 |
| 2024 | 293 | 22 | 17 | 0.70 | 41 | 217 | 298 |
| 2025 | 330 | 29 | 19 | 0.82 | 43 | 219 | 274 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Tactile Systems Technology, Inc., ein Medizintechnikunternehmen, entwickelt und bietet Medizinprodukte zur Behandlung unterversorgter chronischer Erkrankungen in den USA an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 1,086 |
| Headquarters | Minneapolis, MN |
| Address | 3701 Wayzata Boulevard, 55416 Minneapolis, United States |
| Phone | 612 355 5100 |
| Website | tactilemedical.com |
| IPO Date | 28. Jul 2016 |
| ISIN | US87357P1003 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sheri Louise Dodd | CEO, President & Director | 1966 |
| Elaine M. Birkemeyer | Chief Financial Officer | 1975 |
| Kristie T. Burns | Senior Vice President of Business Development | 1972 |
| Jerry A. Sauber | Senior Vice President of Manufacturing, Operations, R&D | – |
| John David Kaercher | Chief Information Officer | – |
| Sunday J. Hoy Esq. | VP of Regulatory Affairs & Chief Compliance Officer | – |
| Aaron R. Snodgrass | Senior Vice President of Sales | – |
| Nicolaus B. Wilson | Senior Vice President of Marketing & Market Access | – |
| Janelle M. Strop | Chief Human Resource Officer | – |
| Antonios P. Gasparis F.A.C.S., M.D. | Chief Medical Officer & Member of Vascular Strategic Advisory Board | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.